Print Page | Close Window


July 25, 2016 - 4:11 p.m.
Gilead Sciences Announces Third Quarter 2016 Dividend
Printer Friendly Version 
July 25, 2016 - 4:09 p.m.
Gilead Sciences Announces Second Quarter 2016 Financial Results
Printer Friendly Version 
July 22, 2016 - 7:19 a.m.
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Printer Friendly Version 
July 21, 2016 - 4:32 p.m.
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Printer Friendly Version 
July 18, 2016 - 5:02 p.m.
Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Printer Friendly Version 
July 08, 2016 - 6:52 a.m.
European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
June 28, 2016 - 10:26 a.m.
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
June 23, 2016 - 7:54 a.m.
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
June 20, 2016 - 8:31 a.m.
Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
June 13, 2016 - 5:01 p.m.
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
Printer Friendly Version 
June 09, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
Printer Friendly Version 
June 07, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
Printer Friendly Version 
May 27, 2016 - 7:27 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
May 24, 2016 - 4:30 p.m.
Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
Printer Friendly Version 
May 20, 2016 - 5:01 p.m.
Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
Printer Friendly Version 
May 09, 2016 - 5:02 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10
Printer Friendly Version 
April 29, 2016 - 8:22 a.m.
European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
Printer Friendly Version 
April 28, 2016 - 4:04 p.m.
Gilead Sciences Announces Second Quarter 2016 Dividend
Printer Friendly Version 
April 28, 2016 - 4:04 p.m.
Gilead Sciences Announces First Quarter 2016 Financial Results
Printer Friendly Version 
April 25, 2016 - 7:11 a.m.
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
Printer Friendly Version 
April 21, 2016 - 5:01 p.m.
Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
Printer Friendly Version 
April 16, 2016 - 7:30 a.m.
Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
Printer Friendly Version 
April 16, 2016 - 6:30 a.m.
Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Printer Friendly Version 
April 15, 2016 - 4:31 a.m.
Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Printer Friendly Version 
April 04, 2016 - 2:58 p.m.
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
Printer Friendly Version 
April 04, 2016 - 8:31 a.m.
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases
Printer Friendly Version 
March 31, 2016 - 2:04 a.m.
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
Printer Friendly Version 
March 10, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
Printer Friendly Version 
March 04, 2016 - 6:00 p.m.
Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Printer Friendly Version 
March 04, 2016 - 4:02 p.m.
Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Printer Friendly Version 
March 01, 2016 - 2:07 p.m.
U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
February 26, 2016 - 7:53 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
February 25, 2016 - 10:38 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
February 24, 2016 - 12:10 p.m.
Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
Printer Friendly Version 
February 23, 2016 - 5:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
Printer Friendly Version 
February 23, 2016 - 12:12 p.m.
Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens
Printer Friendly Version 
February 22, 2016 - 8:32 a.m.
Gilead Launches New Grants Program to Support HIV Cure
Printer Friendly Version 
February 16, 2016 - 8:32 a.m.
U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
Printer Friendly Version 
February 08, 2016 - 5:02 p.m.
Gilead Sciences to Participate in Two Upcoming Investor Conferences
Printer Friendly Version 
February 02, 2016 - 4:02 p.m.
Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
Printer Friendly Version 
February 02, 2016 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results
Printer Friendly Version 
February 01, 2016 - 5:00 p.m.
Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
Printer Friendly Version 
February 01, 2016 - 9:04 a.m.
European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Printer Friendly Version 
January 29, 2016 - 8:00 a.m.
Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director
Printer Friendly Version 
January 26, 2016 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
Printer Friendly Version 
January 19, 2016 - 4:31 p.m.
Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib
Printer Friendly Version 
January 13, 2016 - 1:31 a.m.
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Printer Friendly Version 
January 12, 2016 - 8:31 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
January 08, 2016 - 4:01 p.m.
Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Printer Friendly Version 
January 05, 2016 - 6:01 p.m.
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
Printer Friendly Version 
January 05, 2016 - 8:31 a.m.
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Printer Friendly Version 
January 04, 2016 - 4:31 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection
Printer Friendly Version